Tarek Mekhail, MD

Ariana Pelosci, assistant editor for CancerNetwork®, has been with the team since June 2021. She specializes both in web and print, and runs the social media for CancerNetwork®. 

She is a graduate of the University of Delaware, where she studied Media Communications and minored in journalism and marketing. At heart, she is a Jersey girl, and you can always find her down the shore during her free time. 

Ariana loves to read, specifically historical or contemporary fiction. Follow Ariana on Twitter @APelosci or email her at 

Podcasts

Gregory Riely, MD, PhD, and Tarek Mekhail, MD, detailed the use of mobocertinib of platinum-pretreated patients with metastatic non–small cell lung cancer. 

Between the Lines™ Podcast: Mobocertinib Use in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive mNSCLC

Videos

Closing out their discussion on mobocertinib data and the EXCLAIM cohort, experts share hope for the future management of the EGFR exon 20 insertion–positive mNSCLC. 

Next Steps in the Management of EGFR Exon 20 Insertion–Positive mNSCLC

A brief review of biomarker testing in metastatic non–small cell lung cancer to identify alterations such as the EGFR exon 20 insertion.

mNSCLC: Biomarker Testing and Patient Adherence to TKIs

In the context of mobocertinib clinical data, experts consider factors that help them select therapy and manage therapy for patients with EGFR exon 20 insertion–positive mNSCLC.

EXCLAIM Cohort in mNSCLC: Treatment Selection and Management 

Focused discussion on the safety profile of mobocertinib in platinum-pretreated EGFR exon 20 insertion–positive mNSCLC given data from the EXCLAIM cohort. 

EXCLAIM Cohort: Mobocertinib Safety Data in mNSCLC

Shared insight on efficacy data with mobocertinib from the EXCLAIM cohort of patients with platinum-pretreated EGFR exon 20 insertion–positive mNSCLC.

Efficacy Data From the EXCLAIM Cohort in mNSCLC

Expert oncologists review data from the EXCLAIM cohort, which analyzed mobocertinib use in platinum-pretreated patients with EGFR exon 20 insertion–positive mNSCLC. 

Tarek Mekhail, MD | Authors